Menu Menu

News

Featured
COVID-19 Research Pipeline

52,228

Registered/ Published

2,731

Registered

235

Published

3,673

Registered
As at 1 April 2021
FILTERED BY > Disease-modifying treatments Clear filter

Communique # 40

18 March, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendation for tocilizumab in children or adolescents Further to the Taskforce's recent recommendation for the conditional use of tocilizumab for adults (25 February 2021), the Paediatric and Adolescent Care Panel have reviewed the evidence in the context of this special population, also consulting with members of the Expert Advisory Group in rheumatology, immunotherapy and paediatric...
Communique

Communique # 39

25 February, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE Tocilizumab upgraded to conditional recommendation The Taskforce Disease Modifying Treatment and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated...
Communique

RECOVERY Trial publishes tocilizumab results

12 February, 2021
The Taskforce notes the publication of results of the tocilizumab arm of the RECOVERY trial in medRxiv Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results...
News

Weekly Communique # 33

26 November, 2020
WEEK IN REVIEW Updates to the living guideline Three new recommendations have been published this week covering: Bamlanivimab Fluvoxamine Intravenous immunoglobulin VTE prophylaxis for children and adolescents Further details are...
Communique

Weekly Communique # 29

29 October, 2020
WEEK IN REVIEW Updates to the living guideline this week New recommendations Three new recommendations have been published covering: Triazavirin Other immunomodulatory agents (PIMS-TS) Aspirin and antithrombotic agents...
Communique